Incyte Corporation Company Profile (NASDAQ:INCY)

Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."

Incyte Corporation (NASDAQ:INCY) posted its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. The company earned $326.40 million during the quarter, compared to the consensus estimate of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm's quarterly revenue was up 32.5% compared to the same quarter last year. During the same period last year, the business earned $0.18 EPS. View Incyte Corporation's Earnings History.

Incyte Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Incyte Corporation.

22 equities research analysts have issued 12-month price objectives for Incyte Corporation's shares. Their predictions range from $115.00 to $174.00. On average, they expect Incyte Corporation's stock price to reach $144.75 in the next twelve months. View Analyst Ratings for Incyte Corporation.

Here are some recent quotes from research analysts about Incyte Corporation stock:

• 1. Cowen and Company analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
• 2. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)
• 3. Jefferies Group LLC analysts commented, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and increasing depth from the maturing pipeline building towards broad, more diversified long-term growth opportunities. We continue to see upside potential in 2017 supported by continued Jakafi execution, IDO data/progress, and bari launch enthusiasm, with scarcity value likely continuing to drive M&A speculation. Adjust tgt to $140 from $136." (2/15/2017)

Some companies that are related to Incyte Corporation include Quintiles Transitional Holdings (Q), Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alkermes PLC (ALKS), Icon Plc (ICLR), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), United Therapeutics Corporation (UTHR), Galapagos NV (GLPG), Puma Biotechnology (PBYI), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD) and FibroGen (FGEN).

Incyte Corporation's management team includes the folowing people:

• Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer
• David W. Gryska, Chief Financial Officer, Executive Vice President
• Reid M. Huber, Executive Vice President, Chief Scientific Officer
• Eric H. Siegel, Executive Vice President, General Counsel
• Paula J. Swain, Executive Vice President - Human Resources
• Barry P. Flannelly, Executive Vice President and General Manager , US
• Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development`
• Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry
• Steven H. Stein M.D., Vice President and Chief Medical Officer
• Julian C. Baker, Lead Independent Director

Incyte Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Treasurer State of Michigan (0.03%), Sit Investment Associates Inc. (0.02%), Shikiar Asset Management Inc. (0.01%), Eqis Capital Management Inc. (0.01%), Mutual of America Capital Management LLC (0.01%) and Oakbrook Investments LLC (0.01%). Company insiders that own Incyte Corporation stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Richard S Levy, Steven H Stein and Yao Wenqing. View Institutional Ownership Trends for Incyte Corporation.

Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc., Meeder Asset Management Inc., State Treasurer State of Michigan, Robeco Institutional Asset Management B.V. and Fisher Asset Management LLC. Company insiders that have sold Incyte Corporation stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Herve Hoppenot, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte Corporation.

Incyte Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., Oakbrook Investments LLC, Inverness Counsel LLC NY, Eqis Capital Management Inc. and Mutual of America Capital Management LLC. Company insiders that have bought Incyte Corporation stock in the last two years include Bros Advisors Lp Baker, Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte Corporation.

Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Incyte Corporation stock can currently be purchased for approximately $114.19.